NO20092745L - Mikroniserte partikler av midler med lavdoseringsstyrkeaktive for pulverformuleringer for inhalering - Google Patents

Mikroniserte partikler av midler med lavdoseringsstyrkeaktive for pulverformuleringer for inhalering

Info

Publication number
NO20092745L
NO20092745L NO20092745A NO20092745A NO20092745L NO 20092745 L NO20092745 L NO 20092745L NO 20092745 A NO20092745 A NO 20092745A NO 20092745 A NO20092745 A NO 20092745A NO 20092745 L NO20092745 L NO 20092745L
Authority
NO
Norway
Prior art keywords
inhalation
low dosage
micronized particles
active agents
dosage strength
Prior art date
Application number
NO20092745A
Other languages
English (en)
Other versions
NO346315B1 (no
Inventor
Daniela Cocconi
Rossella Musa
Silivia Catinella
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38120349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092745(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of NO20092745L publication Critical patent/NO20092745L/no
Publication of NO346315B1 publication Critical patent/NO346315B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Oppfinnelsen relaterer seg til mikroniserte partikler med en aktiv ingrediens av lavdoseringsstyrke for anvendelse i tørrpulverformuleringer for inhalasjon og fremgangsmåter for å fremstille dem. Særlig tilveiebringer oppfinnelsen mikroniserte partikler med en aktiv ingrediens av lavdoseringsstryke som enkelt og homogent kan dispergere i en tørrpulverformulering for å bli administrert ved hjelp av en tørrpulverinhalatoranordning. Oppfinnelsen retter seg også mot formuleringer derav i formen av pulvere for inhalering.
NO20092745A 2007-01-10 2007-12-13 Pulverformulering som skal administreres ved å anvende en medium- eller høy-motstands multidose tørrpulverinhalator-anordning NO346315B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07000425A EP1944018A1 (en) 2007-01-10 2007-01-10 Micronised particles of low-dosage strength active agents for powder formulations for inhalation
PCT/IB2007/003892 WO2008084312A2 (en) 2007-01-10 2007-12-13 Micronised particles of low-dosage strength active agents for powder formulations for inhalation

Publications (2)

Publication Number Publication Date
NO20092745L true NO20092745L (no) 2009-07-21
NO346315B1 NO346315B1 (no) 2022-05-30

Family

ID=38120349

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092745A NO346315B1 (no) 2007-01-10 2007-12-13 Pulverformulering som skal administreres ved å anvende en medium- eller høy-motstands multidose tørrpulverinhalator-anordning

Country Status (12)

Country Link
US (1) US8512753B2 (no)
EP (2) EP1944018A1 (no)
DK (1) DK2104490T4 (no)
ES (1) ES2745439T5 (no)
FI (1) FI2104490T4 (no)
HR (1) HRP20191686T4 (no)
HU (1) HUE046677T2 (no)
NO (1) NO346315B1 (no)
PL (1) PL2104490T5 (no)
PT (1) PT2104490T (no)
SI (1) SI2104490T2 (no)
WO (1) WO2008084312A2 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
DE102008037025C5 (de) * 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
EP2191821A1 (en) * 2008-11-26 2010-06-02 CHIESI FARMACEUTICI S.p.A. Microparticles comprising a salt of 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone having improved adhesion properties for dry powder inhalation
CA2759042A1 (en) * 2009-04-24 2010-10-28 Schering Corporation Agglomerate formulations including active pharmaceutical agents with targeted particle sizes
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
AU2009100698B4 (en) * 2009-07-17 2010-04-15 Astrazeneca Ab Combination
WO2011152804A2 (en) 2010-06-03 2011-12-08 Mahmut Bilgic Process for dry powder formulations
WO2012010854A1 (en) * 2010-07-23 2012-01-26 Cipla Limited Inhalation formulations comprising carmoterol in combination with a corticosteroid
EA026267B1 (ru) * 2012-01-25 2017-03-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Композиция в форме сухого порошка, содержащая кортикостероид и бета-адренергическое лекарственное средство, для введения ингаляцией
WO2014007773A1 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions comprising muscarinic receptor antagonist and sorbitol
CN104470503A (zh) 2012-04-13 2015-03-25 葛兰素史克知识产权开发有限公司 聚集粒子
US20150174064A1 (en) * 2012-07-05 2015-06-25 Arven IIac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and glucose anhydrous
UA115989C2 (uk) * 2012-07-05 2018-01-25 Арвен Айлак Санайі Ве Тіджарет А.С. Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
EA201590019A1 (ru) * 2012-07-05 2015-09-30 Арвен Айлак Санайи Ве Тиджарет А.С. Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
WO2014007767A1 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose and a ternary component
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
DE102012221219B4 (de) * 2012-11-20 2014-05-28 Jesalis Pharma Gmbh Verfahren zur Vergrößerung der Partikelgröße kristalliner Wirkstoff-Mikropartikel
RS57799B1 (sr) * 2013-07-11 2018-12-31 Chiesi Farm Spa Formulacija suvog praha za administriranje inhalacijom, koja obuhvata atniholinergik, kortikosteroid i beta-adrenergik
DK3689332T3 (da) 2014-09-09 2026-03-23 Vectura Ltd Formulering, som omfatter glycopyrrolat, fremgangsmåde og apparat
WO2019067708A1 (en) 2017-09-27 2019-04-04 Teva Branded Pharmaceutical Products R&D, Inc. METHOD FOR DECREASING PARTICLE SIZE

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
DK0613371T3 (da) * 1991-12-18 2002-05-13 Astrazeneca Ab Ny kombination af formoterol og budesonid
GB9404945D0 (en) * 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
ITMI991582A1 (it) * 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
ES2471139T3 (es) * 2003-08-06 2014-06-25 Galephar M/F Combinaciones ventajosas para la inhalaci�n de nacistelina y broncodilatadores
ES2309705T3 (es) * 2004-02-06 2008-12-16 MEDA PHARMA GMBH & CO. KG Nueva combinacion de anticolinergico y beta-mimeticos para el tratamiento de enfermedades respiratorias.
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
EP1944018A1 (en) 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation

Also Published As

Publication number Publication date
HRP20191686T1 (hr) 2019-12-27
SI2104490T1 (sl) 2019-10-30
DK2104490T3 (da) 2019-09-02
EP2104490B2 (en) 2024-06-26
US20100055192A1 (en) 2010-03-04
PT2104490T (pt) 2019-09-27
SI2104490T2 (sl) 2024-10-30
EP1944018A1 (en) 2008-07-16
EP2104490A2 (en) 2009-09-30
FI2104490T4 (fi) 2024-09-11
DK2104490T4 (da) 2024-07-01
HRP20191686T4 (hr) 2024-08-02
WO2008084312A2 (en) 2008-07-17
PL2104490T5 (pl) 2024-07-29
ES2745439T5 (es) 2024-12-10
US8512753B2 (en) 2013-08-20
PL2104490T3 (pl) 2019-12-31
EP2104490B1 (en) 2019-07-03
ES2745439T3 (es) 2020-03-02
NO346315B1 (no) 2022-05-30
HUE046677T2 (hu) 2020-03-30
WO2008084312A3 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
NO20092745L (no) Mikroniserte partikler av midler med lavdoseringsstyrkeaktive for pulverformuleringer for inhalering
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
WO2015120110A3 (en) Novel pharmaceutical formulations
MY179703A (en) Dry powder formulation comprising a phosphodiesterase inhibitor
MX2010008234A (es) Nueva dosificacion y formulacion.
AR083208A1 (es) Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion
WO2007123945A3 (en) Mechanical single dose intrapulmonary drug delivery devices
MX2011007817A (es) Formulacion farmaceutica o alimenticia de liberacion controlada y proceso para su preparacion.
TN2014000322A1 (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MY175781A (en) Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
EP2478909A4 (en) PHARMACEUTICAL COMPOSITIONS WITH BISPHOSPHONATE DERIVATIVES AND HIGH DOSE CHOLECALCIFEROL
EP2682102A3 (en) Inhalation Compositions Comprising Corticosteroid and Sorbitol
MY191712A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
PH12014502619A1 (en) Novel dosage and formulation
EP2682098A3 (en) Inhalation Compositions
HK1215167A1 (zh) 可吸入药用组合物和含有该药用组合物的吸入器装置
EP2682100A3 (en) Inhalation Compositions Comprising Muscarinic Receptor Antagonist
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
SA516370446B1 (ar) تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
WO2011093812A3 (en) Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
WO2011093814A3 (en) A pharmaceutical combination comprising formoterol and ciclesonide
TR200907913A2 (tr) İnhalason yolu ile alınmak üzere kuru toz formunda farmasötik bileşim
WO2011093810A3 (en) Dry powder pharmaceutical composition comprising tiotropium and mometasone